ENLIVEN THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$1.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $3.19M, a 35300.00% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$4.46M.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $1.18M.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $814.00K, a 81.30% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$496.00K.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$248.00K, a 103.24% decline from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $7.66M, a 375.14% increase from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $1.61M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.28M 10-Q · filed 2026-08-05 | -$103.00K derived: sum of 3 quarters · filed 2026-08-05 | $711.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$4.46M 10-Q · filed 2026-05-07 | -$3.29M derived: sum of 2 quarters · filed 2026-05-07 | -$2.48M derived: sum of 3 quarters · filed 2026-05-07 | -$2.47M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.99M derived: sum of 2 quarters · filed 2026-03-03 | $2.00M derived: sum of 3 quarters · filed 2026-08-05 | -$496.00K 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | $814.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $823.00K derived: sum of 2 quarters · filed 2026-08-05 | -$1.67M 10-Q · filed 2025-11-12 | -$2.96M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.49M 10-Q · filed 2026-08-05 | -$3.77M derived: sum of 3 quarters · filed 2026-08-05 | $583.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$2.50M 10-Q · filed 2026-05-07 | -$3.78M derived: sum of 2 quarters · filed 2026-05-07 | $574.00K derived: sum of 3 quarters · filed 2026-05-07 | $322.00K derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.07M derived: sum of 2 quarters · filed 2026-03-03 | $2.82M derived: sum of 3 quarters · filed 2026-03-03 | -$248.00K 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | $4.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.10M derived: sum of 2 quarters · filed 2025-11-12 | $1.04M 10-Q · filed 2025-11-12 | $5.82M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | -$252.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$3.32M 10-Q · filed 2025-08-13 | $1.47M derived: sum of 3 quarters · filed 2025-08-13 | $6.10M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | -$3.06M 10-Q · filed 2025-05-14 | $1.72M derived: sum of 2 quarters · filed 2025-05-14 | $6.35M derived: sum of 3 quarters · filed 2025-05-14 | $7.45M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $9.42M derived: sum of 2 quarters · filed 2025-03-13 | $10.52M derived: sum of 3 quarters · filed 2025-03-13 | $7.66M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $4.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $5.73M derived: sum of 2 quarters · filed 2024-11-13 | $2.88M 10-Q · filed 2024-11-13 | $3.54M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.75M 10-Q · filed 2024-08-13 | -$1.09M derived: sum of 3 quarters · filed 2024-08-13 | -$705.00K derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$2.85M 10-Q · filed 2024-05-14 | -$2.19M derived: sum of 2 quarters · filed 2024-05-14 | -$1.80M derived: sum of 3 quarters · filed 2024-05-14 | -$953.00K derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $663.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.05M derived: sum of 2 quarters · filed 2024-03-14 | $1.90M derived: sum of 3 quarters · filed 2024-03-14 | $1.61M 10-K · filed 2024-03-14 | -$4.01M 10-K · filed 2023-02-10 | |||
| 2022-09-30 | $387.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.24M derived: sum of 2 quarters · filed 2023-11-09 | $950.00K 10-Q · filed 2023-11-09 | -$3.55M 10-Q · filed 2022-10-25 | $2.98M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $849.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $563.00K 10-Q · filed 2023-08-10 | -$2.90M 10-Q · filed 2022-08-03 | $2.60M derived: sum of 3 quarters · filed 2023-08-10 | $3.03M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | -$286.00K 10-Q · filed 2023-05-11 | -$1.00K 10-Q · filed 2022-05-06 | $1.75M derived: sum of 2 quarters · filed 2023-06-23 | $2.18M derived: sum of 3 quarters · filed 2023-06-23 | $4.20M derived: sum of 4 quarters · filed 2023-06-23 | |||
| 2021-12-31 | $2.03M derived: 8-K 12 month − 10-Q 9 month · filed 2023-06-23 | $2.46M derived: sum of 2 quarters · filed 2023-06-23 | $4.49M derived: sum of 3 quarters · filed 2023-06-23 | $2.26M 8-K · filed 2023-06-23 | $393.00K 10-K · filed 2022-03-15 | |||
| 2021-09-30 | $430.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $2.46M derived: sum of 2 quarters · filed 2022-10-25 | $229.00K 10-Q · filed 2022-10-25 | $1.08M derived: sum of 4 quarters · filed 2022-10-25 | ||||
| 2021-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$201.00K 10-Q · filed 2022-08-03 | $649.00K derived: sum of 3 quarters · filed 2022-08-03 | $1.08M derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | -$2.23M 10-Q · filed 2022-05-06 | -$1.38M derived: sum of 2 quarters · filed 2022-05-06 | -$947.00K derived: sum of 3 quarters · filed 2022-05-06 | $165.00K derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $850.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $1.28M derived: sum of 2 quarters · filed 2022-03-15 | $2.39M derived: sum of 3 quarters · filed 2022-03-15 | $1.75M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $429.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.54M derived: sum of 2 quarters · filed 2021-11-09 | $898.00K 10-Q · filed 2021-11-09 | $718.00K derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $469.00K 10-Q · filed 2021-08-06 | $289.00K derived: sum of 3 quarters · filed 2021-08-06 | $712.00K derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | -$643.00K 10-Q · filed 2021-05-11 | -$823.00K derived: sum of 2 quarters · filed 2021-05-11 | -$400.00K derived: sum of 3 quarters · filed 2021-05-11 | $62.00K derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | -$180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $243.00K derived: sum of 2 quarters · filed 2021-03-05 | $705.00K derived: sum of 3 quarters · filed 2021-03-05 | $1.30M 10-K · filed 2021-03-05 | ||||
| 2019-09-30 | $423.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $885.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.49M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $462.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $1.06M 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | $600.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |